Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

This study has been completed.

Sponsor:

Collaborator:

Brigham and Women's Hospital

Information provided by:

National Center for Research Resources (NCRR)

ClinicalTrials.gov Identifier:

NCT00004354

First received: October 18, 1999

Last updated: June 23, 2005

Last verified: May 2002

History of Changes

Purpose

OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees.

II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors).

III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA.

IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.

Condition
Hyperaldosteronism


Study Type:	Observational
Study Design:	Primary Purpose: Screening

Resource links provided by NLM:

MedlinePlus related topics: Steroids

Genetic and Rare Diseases Information Center resources: Glucocorticoid-remediable Aldosteronism Hyperadrenalism

U.S. FDA Resources

Further study details as provided by National Center for Research Resources (NCRR):


Study Start Date:	June 1999

Detailed Description:

PROTOCOL OUTLINE:

Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Diagnosed glucocorticoid-remediable aldosteronism (GRA) with hypertension Hypokalemia is variably seen Blood pressure variably elevated Elevated level of aldosterone Low level of plasma renin activity

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004354

Locations


United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Brigham and Women's Hospital

Investigators


Study Chair:	Robert G. Dluhy	Brigham and Women's Hospital

More Information


ClinicalTrials.gov Identifier:	NCT00004354 History of Changes
Other Study ID Numbers:	199/11917 BWH-91328603
Study First Received:	October 18, 1999
Last Updated:	June 23, 2005

Keywords provided by National Center for Research Resources (NCRR):


endocrine disorders genetic diseases and dysmorphic syndromes hyperaldosteronism rare disease

Additional relevant MeSH terms:


Hyperaldosteronism Adrenocortical Hyperfunction Adrenal Gland Diseases Endocrine System Diseases

ClinicalTrials.gov processed this record on July 21, 2017

To Top